Gavin Clark-Gartner analyst EVERCORE

Currently out of the existing stock ratings of Gavin Clark-Gartner, 80 are a BUY (95.24%), 4 are a HOLD (4.76%).

Gavin Clark-Gartner

Work Performance Price Targets & Ratings Chart

Analyst Gavin Clark-Gartner, currently employed at EVERCORE, has had 42.45% of price targets met with an average potential upside of 74.57%, reached in 92 days on average.

Gavin Clark-Gartner has documented 167 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARGX, argenx NV ADR at 22-Oct-2026.

Wall Street Analyst Gavin Clark-Gartner

Analyst best performing recommendations are on LBPH (LONGBOARD PHARMACEUTICALS).
The best stock recommendation documented was for LBPH (LONGBOARD PHARMACEUTICALS) on 12/22/2023. The price target of $25 was fulfilled within 11 days with a profit of $19 (316.67%), with a performance score of 287.88.

Average potential price target upside

ABBV AbbVie ARGX argenx NV ADR ATXS Astria Therapeutics BCRX BioCryst Pharmaceuticals CABA Cabaletta Bio INSM Insmed MIRM Mirum Pharmaceuticals MNMD Mind Medicine RNA Avidity Biosciences SRPT Sarepta Therapeutics TVTX Travere Therapeutics ACRS Aclaris Therapeutics CMPS Compass Pathways Plc CRNX Crinetics Pharmaceuticals DYN Dyne Therapeutics INCY yte KRYS Krystal Biotech LBPH Longboard Pharmaceuticals MGTX MeiraGTx Holdings PLC PRQR ProQR Therapeutics BV TENX VERA Vera Therapeutics VRDN Viridian Therapeutics JSPR Jasper Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Feb-2026

$335

$39.97 (13.55%)

$325

4 days ago
(15-Nov-2026)

Buy Since 17-Nov-2020

$338

$42.97 (14.56%)

$282

18 days ago
(01-Nov-2026)

20/21 (95.24%)

$43.11 (14.62%)

335

Buy Since 07-Dec-2021

$340

$44.97 (15.24%)

$300

18 days ago
(01-Nov-2026)

11/13 (84.62%)

$45.11 (15.30%)

479

Buy Since 05-Apr-2022

$346

$50.97 (17.28%)

$310

18 days ago
(01-Nov-2026)

33/35 (94.29%)

$51.11 (17.33%)

486

Buy Since 15-Nov-2023

$325

$29.97 (10.16%)

$290

18 days ago
(01-Nov-2026)

32/33 (96.97%)

$30.11 (10.21%)

244

Show more analysts

Please expand the browser size to see the chart

Which stock is Gavin Clark-Gartner most bullish on?

Potential upside of $139.05 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Gavin Clark-Gartner most reserved on?

Potential downside of -$35.03 has been obtained for ABBV (ABBVIE)

What Year was the first public recommendation made by Gavin Clark-Gartner?

On 2022
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?